QuidelOrtho Cuts Revenue Guidance Amid Weak Respiratory Season and China Disruptions
Event summary
- QuidelOrtho reported Q1 2026 revenue of $620M, down 10.5% YoY, driven by a 34% decline in Point of Care revenue due to a weaker respiratory season.
- Labs revenue fell 5% YoY, impacted by slower distributor sales in China and Middle East conflict disruptions.
- Immunohematology revenue grew 8% YoY, offsetting declines in other segments.
- Company lowered full-year 2026 revenue guidance to $2.70-$2.75B from $2.7-$2.9B, citing China NHSA IVD pricing guideline changes.
- Completed acquisition of LEX Diagnostics in April, adding an ultra-fast molecular diagnostics platform.
The big picture
QuidelOrtho's Q1 2026 results highlight the volatility in the diagnostics market, with regulatory changes in China and weaker respiratory seasons creating significant headwinds. The company's strategic focus on acquisitions and new product launches aims to offset these challenges, but execution will be key in maintaining long-term growth. The diagnostics sector continues to face geopolitical and regulatory risks that could impact major players like QuidelOrtho.
What we're watching
- Regulatory Headwinds
- The impact of China NHSA IVD pricing guidelines on QuidelOrtho's revenue and profitability in 2026.
- Market Disruptions
- How prolonged Middle East conflict could further disrupt QuidelOrtho's supply chain and sales.
- Strategic Integration
- The pace at which QuidelOrtho can integrate LEX Diagnostics and drive sustainable growth.
Related topics